Skip to main content
Fig. 4 | Biology Direct

Fig. 4

From: Characterization of the symmetrical benzimidazole twin drug TL1228: the role as viral entry inhibitor for fighting COVID-19

Fig. 4

A Effect of TL1228 compound on the viability of VERO E6 cells for three days. MTS assay was carried out to evaluate cell viability after TL1228 administration at a concentration of 60, 40, 30 µM for 72 h compared to untreated cells. At day 3 the treatment with TL1228 60 µM determined a statistically significant decrease in cell viability (p < 0.005). B Time course analyses of VERO E6 cell proliferation treated with 60, 40, 30 µM of TL1228 compound. Cells were seeded in replicates and counted daily. Growth curve of cells was elaborated. The data represent the average ± S.D. of three separate experiments (*p < 0.05)

Back to article page